Xie Jingyuan

Everest Medicines is a leading biopharmaceutical company focused on the development, manufacturing, and commercialization of transformative pharmaceutical products and vaccines in Greater China and other Asian markets. The company has built a robust portfolio of potentially first-in-class or best-in-class molecules across its core therapeutic areas of renal diseases, infectious diseases, and autoimmune disorders. A major milestone for the company is the commercial launch of Nefecon (budesonide delayed-release capsules), the first-in-disease therapy for IgA nephropathy approved in China. Everest Medicines leverages a dual-engine strategy, combining a strong internal R&D engine, particularly in mRNA technology, with strategic licensing and partnerships with global biopharmaceutical leaders.